Biopharmaceutical Company Secures $55 Million Licensing Deal For New Era Cancer Treatment

In an unprecedented move that marks a significant milestone in the fight against cancer, ABVC BioPharma has announced a global licensing agreement that is set to revolutionize oncology and hematology treatment landscapes. The company has entered into a term sheet with OncoX BioPharma, leveraging its innovative oncology/hematology products. This partnership not only forecasts a substantial financial windfall for ABVC BioPharma, with expectations of $55 million in licensing income plus up to $50 million in potential royalties but also signifies a leap forward in cancer therapeutics' accessibility and development. $ABVC BioPharma(ABVC.US)$